keyword
MENU ▼
Read by QxMD icon Read
search

Pain management metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/27878318/-corticosteroids-in-the-management-of-advanced-prostate-cancer
#1
H Kübler
Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone...
November 22, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27843209/radioisotopes-in-management-of-metastatic-prostate-cancer
#2
REVIEW
Amar Raval, Tu D Dan, Noelle L Williams, Andrew Pridjian, Robert B Den
INTRODUCTION: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27694165/bone-targeted-imaging-and-radionuclide-therapy-in-prostate-cancer
#3
Andrei H Iagaru, Erik Mittra, Patrick M Colletti, Hossein Jadvar
Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as (18)F-NaF for the diagnosis of bony disease and (223)RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard (99m)Tc-phosphonates for diagnosis and (153)Sm-ethylenediaminetetramethylene phosphonate or (89)SrCl2 for therapy. The advantages of (18)F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27692731/-prevalence-and-management-of-pain-in-patients-with-metastatic-cancer-in-franche-comt%C3%A3
#4
Fanny Dénommé, Marie Kroemer, Philippe Montcuquet, Gilles Nallet, Antoine Thiery-Vuillemin, Fernando Bazan, Guillaume Mouillet, Cristian Villanueva, Martin Demarchi, Ulrich Stein, Hamadi Almotlak, Loïc Chaigneau, Elsa Curtit, Nathalie Meneveau, Tristan Maurina, Erion Dobi, Thierry Nguyen Tan Hon, Laurent Cals, Laura Mansi, Clotilde Verlut, Héloïse Pana-Katatali, Mathieu Caubet, Marie-Justine Paillard, Samuel Limat, Xavier Pivot, Virginie Nerich
INTRODUCTION: Pain management is a major public health problem, especially in oncology. In order to assess professional practice, the IRFC-FC conducted a survey amongst patients with metastatic osteophilic solid tumor in Franche-Comté. The aims were to assess the pain prevalence, and its characteristics, its management and its impact on patients' quality of life in patients in pain. METHODS: An observational, prospective and multicenter survey was conducted using a self-report questionnaire...
September 29, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27465596/a-rare-case-of-extremely-high-counts-of-circulating-tumor-cells-detected-in-a-patient-with-an-oral-squamous-cell-carcinoma
#5
Xianglei Wu, Romina Mastronicola, Qian Tu, Gilbert Charles Faure, Marcelo De Carvalho Bittencourt, Gilles Dolivet
BACKGROUND: Despite aggressive regimens, the clinical outcome of head and neck squamous cell carcinoma remains poor. The detection of circulating tumor cells could potentially improve the management of patients with disseminated cancer, including diagnosis, treatment strategies, and surveillance. Currently, CellSearch(®) is the most widely used and the only Food and Drug Administration-cleared system for circulating tumor cells detection in patients with metastatic breast, colorectal, or prostate cancer...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27457309/esmo-european-consortium-study-on-the-availability-out-of-pocket-costs-and-accessibility-of-antineoplastic-medicines-in-europe
#6
N Cherny, R Sullivan, J Torode, M Saar, A Eniu
BACKGROUND: The management of cancer is predicated on the availability and affordability of anticancer therapies, which may be either curative or noncurative. AIM: The primary aims of the study were to evaluate (i) the formulary availability of licensed antineoplastic medicines across Europe; (ii) patient out-of-pocket costs for the medications and (iii) the actual availability of the medication for a patient with a valid prescription. MATERIALS AND METHODS: The survey tool was based on the previous ESMO studies that addressed the availability and accessibility of opioids for the management of cancer pain...
August 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27390687/degarelix-for-the-treatment-of-advanced-prostate-cancer-compared-with-gnrh-agonists-a-systematic-review-and-meta-analysis
#7
Seyed Alireza Hosseini, Fatemeh Rajabi, Ali Akbari Sari, Mohsen Ayati, Saeed Heidari, Fawzieh Ghamary
BACKGROUND: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. METHODS: MEDLINE, Web of Science and the Cochrane library were searched to identify all of the published Randomized Controlled Trials (RCTs) that used degarelix versus gonadotropin-releasing hormone agonists with or without anti-androgen therapy for the treatment of prostate cancer...
2016: Medical Journal of the Islamic Republic of Iran
https://www.readbyqxmd.com/read/27385897/metastasis-in-urothelial-carcinoma-mimicking-prostate-cancer-metastasis-in-ga-68-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-a-case-of-synchronous-malignancy
#8
Manoj Gupta, Partha Sarathi Choudhury, Gurudutt Gupta, Jatin Gandhi
Prostate cancer is the second most common cancer in man. It commonly presents with urinary symptoms, bone pain, or diagnosed with elevated prostate-specific antigen.(PSA) levels. Correct staging and early diagnosis of recurrence by a precise imaging tool are the keys for optimum management. Molecular imaging of prostate cancer with Ga-68 prostate-specific membrane antigen.(PSMA), positron emission tomography-computed tomography.(PET-CT) has recently received significant attention and frequently used with a signature to prostate cancer-specific remark...
July 2016: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/27380753/clinical-applications-of-high-intensity-focused-ultrasound
#9
REVIEW
W H She, T T Cheung, C R Jenkins, M G Irwin
Ultrasound has been developed for therapeutic use in addition to its diagnostic ability. The use of focused ultrasound energy can offer a non-invasive method for tissue ablation, and can therefore be used to treat various solid tumours. High-intensity focused ultrasound is being increasingly used in the treatment of both primary and metastatic tumours as these can be precisely located for ablation. It has been shown to be particularly useful in the treatment of uterine fibroids, and various solid tumours including those of the pancreas and liver...
August 2016: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/27244207/spontaneous-healing-of-mandibular-noncontinuous-defect-caused-by-medication-related-osteonecrosis-of-the-jaw
#10
Mürüde Yazan, Fethi Atil, Ismail Doruk Kocyigit, Umut Tekin, Hakan Hifzi Tuz, Melda Misirlioglu
BACKGROUND: Bisphosphonates are used throughout supportive cancer therapies for the treatment of osteoporosis and metastatic bone diseases, but they invariably induce medication-related osteonecrosis of the jaw (MRONJ). This medicational modality may induce consequential losses that can lead to spontaneous or surgical therapy related bone fractures or defects. MRONJ stages and treatment alternatives are described in the current procedures. Accordingly, treatments for stages 0 and 1 are conservative whereas the treatment for stage 3 is surgical resection of the necrotic bone...
June 2016: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/27141135/ivory-vertebra-imaging-findings-in-different-diagnoses
#11
Richard Andreas Braun, Carlos Felipe do Rego Barros Milito, Suzan Menasce Goldman, Eloy de Ávila Fernandes
Low back pain is often managed at all levels of healthcare. In general, diagnostic investigation begins with radiography of the lumbar spine. In addition to the most common findings, radiologists can identify increased density of a vertebral body, referred to as ivory vertebra. The objective of this study was to describe the main diseases that can present with this radiologic sign, such as Hodgkin lymphoma, Paget's disease, metastatic prostate cancer, breast cancer, and osteomyelitis. It is extremely important that radiologists be aware of this finding in order to inform the requesting physician of the possible etiologies, given that it can be the initial radiologic presentation for these diseases...
March 2016: Radiologia Brasileira
https://www.readbyqxmd.com/read/26905032/practical-guidance-on-the-role-of-corticosteroids-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer
#12
Maria De Santis, Fred Saad
Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More recently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is due to their ability to manage adverse effects, reduce symptoms, and improve patients' quality of life. The appropriate selection of available options in mCRPC should be based on careful consideration of a patient's profile and comorbidities...
February 18, 2016: Urology
https://www.readbyqxmd.com/read/26656603/heterogeneity-of-tumor-cells-in-the-bone-microenvironment-mechanisms-and-therapeutic-targets-for-bone-metastasis-of-prostate-or-breast-cancer
#13
REVIEW
Mitsuru Futakuchi, Katsumi Fukamachi, Masumi Suzui
Bone is the most common target organ of metastasis of prostate and breast cancers. This produces considerable morbidity due to skeletal-related events, SREs, including bone pain, hypercalcemia, pathologic fracture, and compression of the spinal cord. The mechanism of bone metastasis is complex and involves cooperative reciprocal interaction among tumor cells, osteoblasts, osteoclasts, and the mineralized bone matrix. The interaction between the metastatic tumor and bone stromal cells has been commonly referred to as the "vicious cycle"...
April 1, 2016: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/26445599/abiraterone-in-the-management-of-castration-resistant-prostate-cancer-prior-to-chemotherapy
#14
REVIEW
Benjamin A Gartrell, Fred Saad
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis...
August 2015: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/26335695/gabapentin-an-analgesic-used-against-cancer-associated-neuropathic-pain-effects-on-prostate-cancer-progression-in-an-in-vivo-rat-model
#15
Ilknur Bugan, Zeynep Karagoz, Seyhan Altun, Mustafa B A Djamgoz
A major problem associated with clinical management of cancer is controlling the accompanying pain, and various analgesics are in common use for this purpose. Recent evidence suggests that some of the targets of analgesics, such as ion channels and receptors, may also be involved in the cancer process, thereby raising the possibility that such use of some analgesics may impact upon cancer itself. The main aim of this study was to determine whether gabapentin, a common adjuvant analgesic in current use against cancer-associated neuropathic pain, would affect tumour development and progression in vivo...
March 2016: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/26262831/management-of-bone-metastases-in-prostate-cancer-a-review
#16
REVIEW
Marc Bienz, Fred Saad
PURPOSE OF REVIEW: Bone metastases in the advanced stages of prostate cancer have a detrimental effect on the quality of life, resulting in skeletal-related events and pain and place a significant burden on healthcare resources. Improvements in prostate cancer treatment have led to a longer survival of patients. Therefore, quality of life is of growing interest and importance. Successful management and prevention of the complications of bone metastasis in those patients remains, however, clinically challenging...
September 2015: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/26119830/targeting-bone-metastases-in-prostate-cancer-improving-clinical-outcome
#17
REVIEW
Jean-Jacques Body, Sandra Casimiro, Luís Costa
Bone metastases develop in most patients with metastatic castration-resistant prostate cancer (mCRPC). They affect the structural integrity of bone, manifesting as pain and skeletal-related events (SREs), and are the primary cause of patient disability, reduced quality of life (QOL) and death. Understanding the pathophysiology of bone metastases resulted in the development of agents that improve clinical outcome, suggesting that managing both the systemic disease and associated bone events is important. Historically, the treatment of CRPC bone metastases with early radiopharmaceuticals and external beam radiation therapy was largely supportive; however, now, zoledronic acid and denosumab are integral to the therapeutic strategy for mCRPC...
June 2015: Nature Reviews. Urology
https://www.readbyqxmd.com/read/25988937/modern-palliative-treatments-for-metastatic-bone-disease-awareness-of-advantages-disadvantages-and-guidance
#18
Andreas F Mavrogenis, Andrea Angelini, Christos Vottis, Elisa Pala, Teresa Calabrò, Panayiotis J Papagelopoulos, Pietro Ruggieri
BACKGROUND: Metastatic disease is the most common malignancy of the bone. Prostate, breast, lung, kidney, and thyroid cancer account for 80% of skeletal metastases. Bone metastases are associated with significant skeletal morbidity including severe bone pain, pathologic fractures, spinal cord or nerve roots compression, and malignant hypercalcemia. These events compromise greatly the quality of life of the patients. The treatment of cancer patients with bone metastases is mostly aimed at palliation...
April 2016: Clinical Journal of Pain
https://www.readbyqxmd.com/read/25880672/cost-of-palliative-external-beam-radiotherapy-ebrt-use-for-bone-metastases-secondary-to-prostate-cancer
#19
Nancy A Nickman, Xiangyang Ye, David K Gaffney, Reed B Barney, Joseph E Biskupiak, Gary J Okano, Vinson C Lee, Jorge Arellano
BACKGROUND: Evaluations of the costs of palliative external beam radiation therapy (EBRT) for treatment of bone metastases are limited. OBJECTIVE: To summarize EBRT lifetime care patterns in deceased men with metastatic prostate cancer treated in a cancer hospital in the United States. METHODS: A retrospective review of electronic health records identified deceased adult prostate cancer (ICD-9 185.xx) patients with bone metastases (ICD-9 198...
March 2015: Journal of Community and Supportive Oncology
https://www.readbyqxmd.com/read/25777571/integrating-bone-targeting-radiopharmaceuticals-into-the-management-of-patients-with-castrate-resistant-prostate-cancer-with-symptomatic-bone-metastases
#20
REVIEW
Seth R Blacksburg, Matthew R Witten, Jonathan A Haas
Metastatic castrate-resistant prostate cancer (CRPC) refers to the disease state in which metastatic prostate cancer fails to respond to androgen deprivation therapy (ADT). This can be manifest as a rising PSA, increase in radiographically measurable disease, or progression of clinical disease. Roughly 90 % of men with metastatic prostate cancer have bone metastases, which is a predictor of both morbidity and mortality. Historically, treatment has been palliative, consisting of external beam radiation therapy (EBRT) and pharmacological analgesics for pain control and osteoclast inhibitors, such as bisphosphonates and denosumab to mitigate skeletal-related events...
March 2015: Current Treatment Options in Oncology
keyword
keyword
76764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"